Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

50
The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
50
Urinary Tract Calculi V: Nursing Management01:28

Urinary Tract Calculi V: Nursing Management

67
AssessmentSubjective Data: Obtain a detailed health history, including any recent or chronic urinary tract infections, periods of immobilization, previous episodes of renal calculi, and medical conditions such as gout, benign prostatic hyperplasia, or hyperparathyroidism. Review the medication history for drugs that may influence stone formation, including allopurinol, analgesics, loop diuretics, or thiazide diuretics. Document the use of long-term indwelling catheters and any past surgical...
67
Urinary Bladder01:23

Urinary Bladder

1.8K
The urinary bladder is a hollow, muscular sac that temporarily stores urine before it is expelled from the body. It can hold approximately 600 mL of urine prior to micturition. The bladder is retroperitoneal and located behind the pubic symphysis in the pelvic floor.
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
1.8K
Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care01:30

Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care

78
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
78
Urodynamic Studies: Uroflowmetry01:19

Urodynamic Studies: Uroflowmetry

960
Uroflowmetry is a non-invasive urodynamic test designed to measure various aspects of urination, including volume, flow rate, and the time to void. This test is crucial for diagnosing and assessing conditions such as bladder outlet obstruction, bladder dysfunction, incomplete bladder emptying, incontinence, and urinary tract blockages caused by benign prostatic hyperplasia (BPH) and urethral strictures.Pre-Test Instructions:Before a uroflowmetry test, patients are typically advised to drink...
960
Imaging Studies VI: Voiding Cystourethrography and Cystography01:22

Imaging Studies VI: Voiding Cystourethrography and Cystography

225
Voiding Cystourethrography (VCUG) and Cystography are specialized radiographic procedures used to examine the structure and function of the bladder and urethra.Voiding Cystourethrography (VCUG)A Voiding Cystourethrogram (VCUG) is a diagnostic imaging procedure that assesses the anatomy and function of the lower urinary tract. It focuses on the bladder, bladder neck, and urethra, helping detect abnormalities such as vesicoureteral reflux (VUR)—the backward or reverse flow of urine into the...
225

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Public perspectives on supervised consumption sites across Canada: A cross-sectional study.

The International journal on drug policy·2026
Same author

Esophageal Cancer Patient Network: a scalable platform for integrating patient voices across the research lifecycle.

Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus·2026
Same author

"We're here, and we're non-judgmental, we're here to save lives": stressors and fulfillment among overdose response hotline operators in Canada.

Harm reduction journal·2026
Same author

Investigating the barriers to uptake and utilization of overdose response hotlines and apps: A study based on data from a national survey.

Digital health·2026
Same author

Cost-effectiveness analysis of Canada's National Overdose Response Service.

BMJ open·2026
Same author

Perceived impacts of Supervised Consumption Sites (SCS) on key service aspects and settings: Reports from Canadian National Questionnaire on Overdose Monitoring (CNQOM).

The International journal on drug policy·2026

Related Experiment Video

Updated: Oct 16, 2025

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.0K

Canadian cost data associated with treating overactive bladder is lacking.

Dylan Viste1, Carly Barton1, Kevin Carlson1

  • 1University of Calgary, Calgary, AB, Canada.

Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada
|October 21, 2021
PubMed
Summary
This summary is machine-generated.

Canadian cost data for overactive bladder (OAB) treatments is scarce, with only one study found. More research is needed to assess the cost-effectiveness of OAB therapies in Canada.

More Related Videos

Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

2.2K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.2K

Related Experiment Videos

Last Updated: Oct 16, 2025

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice
11:46

Urinary Bladder Distention Evoked Visceromotor Responses as a Model for Bladder Pain in Mice

Published on: April 27, 2014

18.0K
Real-Time Void Spot Assay
06:39

Real-Time Void Spot Assay

Published on: February 10, 2023

2.2K
Detrusor Underactivity Model in Rats by Conus Medullaris Transection
03:26

Detrusor Underactivity Model in Rats by Conus Medullaris Transection

Published on: August 28, 2020

2.2K

Area of Science:

  • Health Economics
  • Pharmacoeconomics
  • Urology

Background:

  • Cost-effectiveness analysis is crucial for approving new medical treatments in Canada.
  • Overactive bladder (OAB) treatment cost data is essential for healthcare decision-making.

Purpose of the Study:

  • To identify Canadian-specific cost data for overactive bladder (OAB) treatments based on the Canadian Urological Association (CUA) guideline.
  • To find generalizable cost data from other healthcare jurisdictions for OAB treatments.

Main Methods:

  • Systematic review of peer-reviewed literature.
  • Included studies from OECD countries (excluding U.S.) published in English since January 2009.

Main Results:

  • 18 studies were included from 165 abstracts.
  • Only one Canadian study reported costs (Canadian dollars) for second-line OAB treatments.
  • No studies reported costs for first-line treatments; gaps identified for select second- and third-line CUA-recommended treatments.

Conclusions:

  • Canadian peer-reviewed literature lacks sufficient cost data for OAB treatments.
  • Existing Canadian data is limited to a single study on second-line therapies from over a decade ago.
  • Generalizability of international cost data for third-line OAB treatments to Canada is uncertain.